|
|
| 218.16 Net Asset Value | -0.84% 1 Day | +20.05% Year-to-Date | Overall Morningstar Rating |
| Health Style or Category | No Load Sales Expenses | 0.81% Expense Ratio | High Morningstar Risk Rating™ |
| 1 month | +4.79% | 3 years | +46.67% | |
| 3 months | +24.57% | 5 years | +34.23% | |
| 1 year | +71.76% | Since inception | +14.75% |
| FBIOX | Category | |
|---|---|---|
| Performance 5-yr return | +34.23% | +20.87% |
| Expense ratio | 0.81% | 1.46% |
| Risk 5 year sharpe ratio | 1.59 | 1.70 |
| Net assets | $11.0B | $2.6B |
| Average market cap | $10.6B | $28.7B |
| Average P/E | 32.3 | 26.6 |
| Portfolio turnover | 42% | 42% |
There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.
| Fund family | Fidelity Investments |
| Fund manager & tenure | Rajiv Kaul / 8 Years |
| Minimal initial investment | $2,500.00 |
| Minimum IRA investment | $200.00 |
| U.S. stock | 97.77% |
| International stock | 1.86% |
| Cash | 0.20% |
| Other | 0.17% |
| Fixed income | 0.00% |
| Healthcare | 100.00% |
| Business service | 0.00% |
| Consumer goods | 0.00% |
| Consumer service | 0.00% |
| Energy | 0.00% |
| GILD Gilead Sciences Inc | 14.47% |
| AMGN Amgen Inc | 9.31% |
| BIIB Biogen Idec Inc | 6.53% |
| CELG Celgene Corporation | 4.78% |
| ALXN Alexion Pharmaceuticals, Inc. | 4.49% |
| ICPT Intercept Pharmaceuticals Inc | 4.10% |
| REGN Regeneron Pharmaceuticals, Inc. | 3.22% |
| VRTX Vertex Pharmaceuticals Inc | 3.22% |
| MDVN Medivation, Inc. | 1.95% |
| PCYC Pharmacyclics, Inc. | 1.70% |
.
